Details of trial outcomes
| TIPSS | TIPSS+VBL | TIPSS/TIPSS+VBL relative hazard over entire follow up (95% CI)* | p Value* | |
|---|---|---|---|---|
| *TIPSS versus TIPSS+VBL. The first value refers to uncontrolled analysis. The second value refers to analysis controlled for sex and pre-TIPSS portal pressure gradient. | ||||
| **p = 0.386 for comparisons in the first six months of follow up only. | ||||
| Mortality (n (%)) | 1.31 (0.66–2.61)/1.10 (0.53–2.28) | 0.434/0.803 | ||
| 6 month | 5 (13%) | 2 (5%) | ||
| 12 month | 8 (21%) | 6 (15%) | ||
| 24 month | 14 (36%) | 11 (28%) | ||
| Variceal rebleeding (n (%)) | 0.58 (0.15–2.33)/0.39(0.09–1.77) | 0.440/0.221 | ||
| 6 month | 0 | 3 (8%) | ||
| 12 month | 1 (3%) | 5 (13%) | ||
| 24 month | 3 (8%) | 6 (15%) | ||
| Hepatic encephalopathy (n (%)) | 2.63 (1.11–6.25)/2.10 (0.79–5.58) | 0.023**/0.136 | ||
| 6 month | 5 (13%) | 3 (8%) | ||
| 12 month | 10 (26%) | 3 (8%) | ||
| 24 month | 14 (26%) | 7 (18%) | ||